Kezar Life Sciences (KZR) Amortization of Deferred Charges (2021 - 2025)

Kezar Life Sciences (KZR) has disclosed Amortization of Deferred Charges for 5 consecutive years, with -$62000.0 as the latest value for Q4 2025.

  • For Q4 2025, Amortization of Deferred Charges fell 193.94% year-over-year to -$62000.0; the TTM value through Dec 2025 reached $176000.0, down 32.05%, while the annual FY2025 figure was $176000.0, 32.05% down from the prior year.
  • Amortization of Deferred Charges hit -$62000.0 in Q4 2025 for Kezar Life Sciences, down from $37000.0 in the prior quarter.
  • Across five years, Amortization of Deferred Charges topped out at $159000.0 in Q1 2025 and bottomed at -$62000.0 in Q4 2025.
  • Average Amortization of Deferred Charges over 5 years is $57235.3, with a median of $59000.0 recorded in 2023.
  • On a YoY basis, Amortization of Deferred Charges climbed as much as 148.44% in 2025 and fell as far as 193.94% in 2025.
  • Kezar Life Sciences' Amortization of Deferred Charges stood at $91000.0 in 2021, then tumbled by 40.66% to $54000.0 in 2022, then rose by 9.26% to $59000.0 in 2023, then grew by 11.86% to $66000.0 in 2024, then tumbled by 193.94% to -$62000.0 in 2025.
  • According to Business Quant data, Amortization of Deferred Charges over the past three periods came in at -$62000.0, $37000.0, and $42000.0 for Q4 2025, Q3 2025, and Q2 2025 respectively.